Zelboraf is an oral, small molecule, kinase inhibitor indicated for the treatment of patients with inoperable or metastatic melanoma with BRAF V600 mutations.
Zelboraf is not recommended for use in melanoma patients with wild-type BRAF.
Approved in the US, EU and Switzerland
Looking for more detailed information?
For regulatory reasons we are not able to provide further details on our products on this website, but more information may be available on our local website.
Please choose your country of residence to access available information in your language.